CALGARY, Alberta: Orpyx® Medical Technologies announced today that its sensory insoles, analytics platform, and remote monitoring program will be used in a new clinical trial funded by the National Institutes of Health (NIH). The WIREDUP: Wearable Insoles for Recurrent Diabetic Ulcer Prevention study will be led by Johns Hopkins University School of Medicine, with collaborators from Keck Medicine of USC and the University of Utah Spencer Fox Eccles School of Medicine.

The $5 million R01-funded randomized controlled trial will enroll 400 participants to test whether integrating digital foot monitoring into routine care can help reduce the incidence of diabetic foot ulcers (DFUs), one of the most costly and serious complications of diabetes. More than 80% of lower extremity amputations are preceded by a DFU, making prevention a critical research priority.

Orpyx is providing the full digital health platform for the study, which includes sensory insoles to capture plantar pressure, temperature, and activity data; analytics to identify patterns of concern; and a remote monitoring program to enable timely escalation of care. Study oversight, data collection, and analysis will remain entirely with the independent academic research team.

“Supporting independent, peer-reviewed research is central to advancing care for people with diabetes,” said Dr. Breanne Everett, CEO and founder of Orpyx Medical Technologies. “We are honored that our platform has been selected for use in this NIH-funded trial, which will generate high-quality evidence to inform the role of digital tools in diabetic foot ulcer prevention.”

About Orpyx Medical Technologies Inc.

Orpyx® is a health technology company helping people with diabetes stay on their feet and preserve independence through its patented sensor-enabled smart insole system and integrated remote monitoring program. Built to detect early warning signs and prompt timely intervention, the Orpyx continuous foot monitoring solution helps improve adherence, reduce total costs, and preserve mobility and quality of life. The company partners with VA Medical Centers, health systems, and payers across North America to deliver clinically validated outcomes and cost savings at scale.

Fonte: Business Wire